Treatment Options in Metastatic Castration-Resistant Prostate Cancer
In this K-Cast video series, Neal Shore, MD, describes current standards in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and provides an overview of data from the PROfound trial. Also discussed are genetic testing in mCRPC, the impact of coronavirus disease 2019 on patient care, the role of PARP inhibitors in patients with mCRPC, and considerations for the management of mCRPC.
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5